Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06906874

Activated Charcoal Use in Chronic Kidney Disease Patients

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

End Stage Renal Disease (ESRD) Avitaminosis Bone Diseases Bone Diseases, Metabolic CKD 5D, Hemodialysis CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder Calcium Metabolism Disorders Chronic Disease Chronic Kidney Disease-Mineral and Bone Disorder Deficiency Diseases Disease Attributes Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hyperparathyroidism Hyperparathyroidism, Secondary Kidney Diseases Kidney Failure, Chronic Male Urogenital Diseases Malnutrition Metabolic Diseases Musculoskeletal Diseases Nutrition Disorders Nutritional and Metabolic Diseases Parathyroid Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Rickets Urogenital Diseases Urologic Diseases Vitamin D Deficiency

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Urology and Nephrology Center

Al Mansurah, Please Select, Egypt

Location status: Recruiting

Location contact

Urology and Nephrology Center Urology and Nephrology Center

CONTACT

[email protected]

+201207753307

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult aged ≥18 years with ESRD.
  • Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.
  • Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).

Exclusion criteria

  • Severely malnourished (as diagnosed by the department's dietitian).
  • Treated with overnight dialysis.
  • Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL.

Treatment and study plan

Activated Charcoal

Drug

oral activated charcoal capsules

Phosphate Binders

Drug

calcium-based or non-calcium based (sevelamer) binders

Primary outcomes

  1. Serum phosphorus levels

    Time frame: 8 weeks

    Difference between two groups of serum phosphorous level in mg/dL at the end of the study.

Secondary outcomes

  1. The percentage of patients who achieved decreasing at least 3 points in The Worst Itching Intensity Numerical Rating Scale (WI NRS)

    Time frame: 8 weeks

    The (WI-NRS) is a validated 11-point scale, with scores ranging from 0 to 10 and with higher scores indicating greater itch intensity.

Study contacts

Contact information is provided by the study sponsor or research team.

Basma M. Sayed Ahmed, M.Sc.

CONTACT

[email protected]

+201207753307

Sponsors and collaborators

Lead sponsor

Mansoura University

Other

Registry information

Official study title

Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 2, 2025
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.